Potential Therapy for IPF and Fatty Liver Disorders Shows Safety in Early Clinical Trial
DS Biopharma, headquartered in Dublin, Ireland, and focused on therapies for inflammatory and fibrotic skin and pulmonary disorders, recently announced that a Phase 1 clinical trial evaluating safety and dosing levels for its drug candidate DS102 (15-HEPE) has been successfully completed. DS102 is an oral bioactive lipid drug developed as…